← All trials
NCT03077451
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 13, 2017
- Primary completion
- Oct 1, 2019
- Completion date
- Nov 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- AIDS Malignancy ConsortiumLead sponsor
- AIDS Malignancy ConsortiumOverall official - principal investigator
- National Cancer Institute (NCI)Collaborator
- The EMMES CorporationCollaborator
- University of California, Los AngelesCollaborator
- Hoosier Cancer Research NetworkCollaborator
- AIDS and Cancer Specimen ResourceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.